Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing investor, BDC Capital.
“We’re very pleased to have completed this Series B financing”, commented Tom Reeves, President & CEO of Interface Biologics. “Having a strategic investor like DSM in combination with BDC underscores both IBI’s success to date and the confidence that our investors have in our future. We look forward to working with DSM as we continue the commercial development of our surface modifying macromolecules and our drug delivery polymer technology platforms.”
Interface Biologics is a University of Toronto spinoff located at the MaRS Centre in Toronto, Canada and is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.
For more information, please visit: www.interfacebiologics.com